Regulatory Story

RNS Number : 7531K

Shield Therapeutics PLC

11 July 2017

Shield Therapeutics plc

("Shield" or the "Company")

Grant of Share Options

London, UK, 11 July 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that the Company has today granted, in aggregate, 1,972,487 share awards in the form of options over Ordinary shares in the capital of the Company ("Ordinary Shares") under the Company's 2016 Long-term Incentive Plan ("LTIP") and the 2016 Company Share Option Plan ("CSOP"). The Company has granted 1,683,877 options under the LTIP and 288,610 options under the CSOP.

The LTIP options will be exercisable at a price of 1.5 pence per Ordinary Share, after a period of 3 years until the day before the tenth anniversary of the grant, subject to the achievement of clear performance criteria set out in the Company's Admission Document, a copy of which is available on the Company's website (www.shieldtherapeutics.com).

The CSOP options are exercisable at an exercise price of 157.5 pence per Ordinary Share from the third anniversary of grant until the day before the tenth anniversary of grant. There are no additional performance conditions attaching to the CSOP options.

This grant of options is part of the Company's long-term incentive arrangements designed to align the interests of the shareholders and executives.

In accordance with the requirements of the EU Market Abuse Regulation the following options have been granted to PDMRs under the LTIP and CSOP.

Name

LTIP options granted

Total number of LTIP options held following grant

CSOP options granted

Total number of CSOP options held following grant

Carl Sterritt, CEO

263,512

572,736

19,048

19,048

Joanne Estell, CFO

285,714

285,714

19,048

19,048

Paul Steckler, PDMR

162,698

356,618

19,048

19,048

Mark Sampson, PDMR

165,952

321,088

19,048

19,048

Following the grant of the LTIP and CSOP options, the total number of Ordinary Shares outstanding under share incentive schemes arrangements will be 3,014,749 representing 2.59% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Option over ordinary shares of 157.5p each in the capital of the Company

ISIN of Ordinary Shares: GB00BYV81293

b)

Nature of the transaction

Grant of Options over ordinary shares in accordance

with the Company's Share Option Scheme

c)

Price(s) and volume(s)

Exercise price: 157.5p

Volumes:

Carl Sterritt 19,048

Joanne Estell 19,048

Paul Steckler 19,048

Mark Sampson 19,048

d)

Aggregated information

-Aggregated volume

-Price

76,192

Exercise price: 157.5p

e)

Date of the transaction

11 July 2017

f)

Place of the transaction

Outside a trading venue

-Ends-

For further information please contact:

Shield Therapeutics plc

+44 (0)207 186 8500

Carl Sterritt, Chief Executive Officer

Joanne Estell, Chief Financial Officer

Nominated Advisor and Joint Broker

Liberum Capital Limited

Christopher Britton/Steve Pearce

+44 (0)20 3100 2222

Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

Financial PR Advisor

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

+44 (0)20 3709 5700

shieldtherapeutics@consilium-comms.com

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights untilthemid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visitwww.shieldtherapeutics.com.